Therapeutic targeting of EPH receptors and their ligands

273Citations
Citations of this article
256Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Critical roles for EPH receptor (EPH)-ephrin signalling in a range of chronic and regenerative diseases are increasingly being recognized. In particular, the complex roles of EPHs and ephrins in tumour growth and progression, and in nerve injury and regeneration have been studied extensively. This has led to considerable progress in developing strategies for their therapeutic targeting, with some anticancer agents already in clinical trials. Promising leads for non-malignant diseases are also emerging, with compelling preclinical data encouraging clinical development. We discuss this rapidly developing area of drug discovery, highlighting the associated challenges and limitations. © 2014 Macmillan Publishers Limited. All rights reserved.

Cite

CITATION STYLE

APA

Boyd, A. W., Bartlett, P. F., & Lackmann, M. (2014, January). Therapeutic targeting of EPH receptors and their ligands. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd4175

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free